Exciting news that will forever change the way we approach and treat corneal weakening diseases such as keratoconus and corneal ectasia! The FDA has approved the Avedro KXL Corneal Collagen Cross-Linking System (www.avedro.com), and the Princeton Eye Group will be only one of a handful of sites in the country to launch this technology. Dr. Miedziak was one of only two investigators in NJ participating in the FDA-monitored trials, and by so doing, learned how this technology can often arrest keratoconus and corneal ectasia. There were some stunning success stories in patients who previously could not be treated. This specialized non-incisional technique utilizes riboflavin assisted UV-light emission cross-links collagen in the cornea, thereby stiffening it and often flattening extremely steep curvatures.